Hologic Completes Acquisition of Mobidiag
By LabMedica International staff writers Posted on 24 Jun 2021 |
Illustration
Hologic, Inc. (Marlborough, MA, USA) has completed its previously announced acquisition of Mobidiag Ltd. (Espoo, Finland), an innovator in near-patient, acute care molecular diagnostic testing, for an enterprise value of approximately USD 808 million.
Hologic is a medical technology company focused on improving women's health and well-being through early detection and treatment. Mobidiag provides near-patient, molecular diagnostic instruments and tests for acute care conditions including gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare associated infections. Its Amplidiag and Novodiag testing platforms deliver results in 50 minutes to two hours. The Novodiag platform combines real-time PCR and microarray capabilities to provide high-level multiplexing. Multiplexing enables multiple pathogens to be identified in a single sample, streamlining workflows for laboratories and providing rapid results to physicians.
“Closing the acquisition of Mobidiag enables us to become a broader, more diversified global diagnostics leader,” said Jan Verstreken, group president, international at Hologic. “Together, we can accelerate development and adoption of Mobidiag’s innovative products globally and drive Hologic’s growth.”
Related Links:
Hologic, Inc.
Mobidiag Ltd.
Hologic is a medical technology company focused on improving women's health and well-being through early detection and treatment. Mobidiag provides near-patient, molecular diagnostic instruments and tests for acute care conditions including gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare associated infections. Its Amplidiag and Novodiag testing platforms deliver results in 50 minutes to two hours. The Novodiag platform combines real-time PCR and microarray capabilities to provide high-level multiplexing. Multiplexing enables multiple pathogens to be identified in a single sample, streamlining workflows for laboratories and providing rapid results to physicians.
“Closing the acquisition of Mobidiag enables us to become a broader, more diversified global diagnostics leader,” said Jan Verstreken, group president, international at Hologic. “Together, we can accelerate development and adoption of Mobidiag’s innovative products globally and drive Hologic’s growth.”
Related Links:
Hologic, Inc.
Mobidiag Ltd.
Latest Industry News
- Beckman Coulter Partners with BioPorto for Global Distribution of Acute Kidney Injury NGAL Tests
- CACLP 2025 New Date and Venue Announced
- Roche to Develop New Diagnostic Technologies for Traumatic Brain Injuries
- LGC Clinical Diagnostics and AccuGenomics Collaborate on Enhancing Cancer Testing Accuracy
- Beckman Coulter and SphingoTec Partner to Improve Kidney Health Assessment in Critical Care
- Seegene and Werfen Finalize Partnership Agreement on Technology-Sharing Initiative
- Cepheid Partners with Fleming Initiative to Fight Antimicrobial Resistance
- MEDICA LABMED FORUM 2024: International Experts Meet to Discuss Trending Topics in Laboratory Medicine
- Nova Biomedical and Terumo BCT Collaborate on Automated Cell Culture Sensing
- Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership
- Roche Expands Digital Pathology Open Environment with Integration of Advanced AI Algorithms from New Collaborators
- Qiagen and Eli Lilly to Develop First QIAstat-Dx IVD Panel for Neurodegenerative Applications
- QIAGEN and AstraZeneca Expand Collaboration into New Disease Areas
- MEDICA 2024 + COMPAMED 2024: Adapted Hall Layout for Better Integration
- Global Coagulation Testing Driven by Increasing Blood Disorders and Surgical Interventions
- Sysmex and QIAGEN Expand Collaboration in Genetic Testing